Peptide Receptor Radionuclide Therapy (PRRT) in the management of patients with ectopic Cushing’s syndrome due to metastatic gastroenteropancreatic neuroendocrine neoplasia (GEPNEN): A single centre experience

#3952

Introduction: Metastatic GEPNEN can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and often refractory to medical therapy. Bilateral adrenalectomy (BA) carries risk and long-term morbidity. Patients (pts) unsuitable for surgery have dismal outcomes. Peptide receptor radionuclide therapy (PRRT) is a rational option for hormone control in ECS caused by NEN with high somatostatin receptor (SSTR) expression yet detailed case series to guide its use are lacking.

Aim(s): We aim to describe outcomes of pts with ECS treated with PRRT including ECS control, progression free and overall survival.

Materials and methods: Single-centre, retrospective analysis of imaging, biochemistry, and clinical outcomes of 7 consecutive pts with ECS caused by metastatic GEPNEN treated with PRRT from 2006-2023.

Conference:

Presenting Author: Boehm E

Authors: Boehm E, Hung T, Akhurst T, Alipour R, Cardin A,

Keywords: GEPNEN, PRRT, Ectopic Cushing's Syndrome,